

RCE \$

PTO/SB/30 (09-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Request For Continued Examination (RCE) Transmittal Address to: MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Application Number	09/810,927-Conf. #7150
	Filing Date	March 16, 2001
	First Named Inventor	Eugene Medlock
	Art Unit	1646
	Examiner Name	J. Anders
	Attorney Docket No.	01017/36917A

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

ii. ☐ Other _____

b. ☒ Enclosed

i. ☒ Amendment/Reply

iii. ☒ Information Disclosure Statement (IDS)

ii. ☐ Affidavit(s)/Declaration(s)

iv. ☐ Other _____

2. **Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

b. ☐ Other _____

3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

a. ☐ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. _____

i. ☒ RCE fee required under 37 CFR 1.17(e)

ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17)

iii. ☐ Other _____

b. ☒ Check in the amount of \$ 1,720.00 enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Name (Print/Type)	Sharon M. Sintich	Registration No. (Attorney/Agent)	48,484
Signature		Date	January 28, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 28, 2004

Signature: (Sharon M. Sintich)


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date shown below.

Dated: January 28, 2004

Signature:

(Sharon M. Sintich)

RECEIVED
FEB 05 2004
TECH CENTER
Docket No. 20101736917A
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Eugenc Medlock, et al.

Application No.: 09/810,927

Group Art Unit: 1646

Filed: March 16, 2001

Examiner: J. Anders

For: IL-17 RECEPTOR LIKE MOLECULES AND
USES THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)
PURSUANT TO 37 CFR §§1.56, 1.97 AND 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Submitted herewith is a PTO-Form SB/08A listing documents A1-A3 and B9-B15. Copies of all listed documents are enclosed herewith. The Applicants wish to draw the Examiner's attention to these documents and respectfully request that these documents be made of record and considered for the above-identified application.

This Supplemental Information Disclosure Statement is being submitted with a Request for Continued Examination under 37 C.F.R. §1.14. Therefore, the Applicants believe no fee is due with this statement. However, the commissioner is authorized to charge any fee due under 37 C.F.R. §1.97(c) to Deposit Account No. 13-2855.

Dated: January 28, 2004

Respectfully submitted,

By 
Sharon M. Sintich

Registration No. 48,484

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, 6300 Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agents for Applicants


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date shown below.

Dated: January 28, 2004

Signature:

(Sharon M. Sintich)

Docket No.: 01017/36917A
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Eugene Medlock, et al.

RECEIVED

Application No.: 09/810,927

Group Art Unit: 1646 FEB 05 2004

Filed: March 16, 2001

Examiner: J. Anders TECH CENTER 1600/2900

For: IL-17 RECEPTOR LIKE MOLECULES AND
USES THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)
PURSUANT TO 37 CFR §§1.56, 1.97 AND 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Submitted herewith is a PTO-Form SB/08A listing documents A1-A3 and B9-B15. Copies of all listed documents are enclosed herewith. The Applicants wish to draw the Examiner's attention to these documents and respectfully request that these documents be made of record and considered for the above-identified application.


This Supplemental Information Disclosure Statement is being submitted with a Request for Continued Examination under 37 C.F.R. §1.14. Therefore, the Applicants believe no fee is due with this statement. However, the commissioner is authorized to charge any fee due under 37 C.F.R. §1.97(c) to Deposit Account No. 13-2855.

Dated: January 28, 2004

Respectfully submitted,

By 
Sharon M. Sintich

Registration No.: 48,484
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, 6300 Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agents for Applicants



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/810,927
Filing Date	March 16, 2001
First Named Inventor	Medlock et al.
Art Unit	1646
Examiner Name	J. Anders
Attorney Docket Number	0101/36917A

RECEIVED**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number-Kind Code (if known)			
	A1	6,482,923	11-19-2002	Shi et al.	
	A2	6,635,443	10-21-2003	Shi et al.	
	A3	6,548,633	04-15-2003	Edwards et al.	

FEB 06 2004

TECH CENTER 10-10-2000

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T
		Country Code-Number-Kind Code (if known)			
	B9	WO 01/90358	11-29-2001	Schering Corporation	
	B10	WO 01/16318	03-08-2001	Genentech, Inc.	
	B11	WO 01/68848	09-21-2001	Genentech, Inc.	
	B12	WO 00/37491	06-29-2000	Genset, Inc.	
	B13	WO 01/00806	01-04-2001	Genset, Inc.	
	B14	WO 01/49728	07-12-2001	Hyseq, Inc.	
	B15	WO/0015759	03/23/2000	Human Genome Science	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant